Web Results

Merck & Co., Inc. v. Reynolds : SCOTUSblog


Apr 27, 2010 ... Merck & Co., Inc. v. ... Joint Appendix Volume I · Brief for Respondent Richard Reynolds, et al. Reply Brief for Petitioner Merck & Co. ... Brief for Dr. Harlan M. Krumholz and Dr. Joseph S. Ross in Support of Respondents ...

Bristol-Myers Squibb Co. et al v. Merck & Co Inc. - Law360


Parties, docket activity and news coverage of federal case Bristol-Myers Squibb Co. et al v. Merck & Co Inc., case number 1:14-cv-01131, from Delaware Court.

2016 Southern District of New York U.S. Federal District Court Case ...


Del Giudice et al v. Harlan et al ... Company v. National Union Fire Insurance Company of Pittsburgh, PA et al ... Docket Number: 1:2011cv04947. Urena v. Swiss Post Solutions, Inc. et al. Date: September 21 ..... Merck & Co., Inc. v. Pericor ...

Opinions Author/Dissent | Eighth Circuit | United States Court of ...


[ 05-4217 ] Mary Plubell v. Merck & Co., Inc. [ 05-4489 ] ... [ 06-1904 ] Douglas Wood, et al. v. Foremost Insurance ..... [ 09-2769 ] United States v. Suresh Harlan Small.

What have we learnt from Vioxx? - NCBI - National Institutes of Health


Harlan M Krumholz, Harold H Hines Junior professor of medicine and ... Rofecoxib (Vioxx) was introduced by Merck in 1999 as an effective, safer ..... Letter re: financial disclosure for Merck and Co, Inc sponsored protocol entitled: ... et al. re: fw: for review [peer]: 2001-ms-2470 (full paper) - due date Monday, 27 August 2001.

Kirkland & Ellis LLP > Lefkowitz, P.C., Jay P.


Harlan Fiske Stone Scholar (1985-86) ... West-Ward Pharmaceuticals, Inc. et al.; Yamane v. .... 180 days of marketing exclusivity for its generic version of Merck's blockbuster drug Zocor following Merck's request to remove the patents claiming  ...

Pooled Analysis of Rofecoxib Placebo-Controlled Clinical ... - NCBI


Nov 23, 2009 ... Merck, the maker of rofecoxib, promoted it as a safer alternative to .... plaintiffs and against Merck and Co., Inc. While the authors obtained access to the .... Our analysis builds upon the prior work of Jüni et al., published shortly .... Cona v. Merck and Co., Inc.] 2000. Mar 9 [Last Accessed December 1, 2008].

The ADVANTAGE Seeding Trial: A Review of Internal Documents ...


Aug 19, 2008 ... During Cona v Merck and Co., Inc., and McDarby v Merck and Co., Inc., ..... Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. ..... MD, MHS; Joseph S. Ross, MD, MHS; David S. Egilman, MD, MPH; and Harlan M.

Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data ...


Nov 23, 2009 ... ... MHS; David S. Egilman, MD, MPH; Yongfei Wang, MS; Harlan M. Krumholz, MD, SM ... Merck & Co Inc, Whitehouse Station, New Jersey (hereinafter, ..... Our analysis builds on the prior work of Jüni et al, published shortly after .... of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis.

Promoting Transparency in Pharmaceutical Industry–Sponsored ...


Documents were identified that suggested the company was tracking and .... less common in the naproxen group than in the rofecoxib group (0.1 percent vs. ..... request of plaintiffs in litigation against Merck and Co., Inc. related to rofecoxib in the United States from 2006 to 2007. ... Bhandari M, Busse JW, Jackowski D. et al .

More Info

Merck Drug Patents Asserted Against Gilead Valid, Jury Finds ...


Mar 22, 2016 ... The case is Gilead Sciences Inc. v. Merck & Co. Inc. et al., case number 5:13-cv- 04057, in the U.S. District Court for the Northern District of ...

Mayne Pharma International Pty Ltd. v. Merck & Co., Inc., et al


Parties, docket activity and news coverage of federal case Mayne Pharma International Pty Ltd. v. Merck & Co., Inc., et al, case number 1:15-cv-00438, from  ...

Exhibits 3 to 3A - Merck Vioxx - Home


May 4, 2016 ... V. Max Berger Led Plaintiffs' Settlement Negotiations, and .... Merck & Co., Inc., et al., No. ..... Reply Brief for Petitioners, Merck & Co., Inc. v. .... Drs. Harlan M. Krumholz, M.D., S.M., and Joseph S. Ross, M.D., M.H.S.: Dr.